Biogen EVP Chirfi Guindo to depart June 30; say-on-pay passes with 48% against

BIOGEN INC.

Chirfi Guindo, EVP Global Product Strategy, leaves June 30, 2022 for a role outside Biogen.
All 11 director nominees elected; Richard Mulligan received 77.4M for, 38.3M against.
PwC ratified as 2022 auditor with 123.8M votes for and 2.3M against.
Advisory say-on-pay approved: 60.1M for, 55.3M against (47.9% against), indicating shareholder concern.
No other material changes reported.

item 5.02 item 5.07 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Chirfi Guindo

Executive Vice President for Global Product Strategy and Commercialization

BIIB · BIOGEN INC.

Effective: 2022-06-30
Filed: June 21, 2022, 7:59 PM ET

On June 21, 2022, Chirfi Guindo, Executive Vice President for Global Product Strategy and Commercialization announced that he has accepted a new role outside of Biogen, Inc. (the “Company”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Chirfi Guindo departed as Executive Vice President for Global Product Strategy and Commercialization at BIOGEN INC..

Action: departing
Role: Executive Vice President for Global Product Strategy and Commercialization

Exact text from the filing

On June 21, 2022, Chirfi Guindo, Executive Vice President for Global Product Strategy and Commercialization announced that he has accepted a new role outside of Biogen, Inc. (the “Company”).

View on SEC.gov

BIOGEN INC. filing history →

Source: SEC EDGAR

accession 0001193125-22-177791

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.